2025-06-05-Jefferies-萨纳（SANA）_SANA在2025年杰富瑞医疗会议_1型糖尿病仍是重点_在2025年美国糖尿病协会会议上有6个月随访数据_7页_107kb

Company Overview: Sana Biotechnology is a clinical-stage biotech firm focused on engineered cell therapies for gene repair and cell replacement, with a primary emphasis on Type 1 Diabetes (T1D) through its UP421 program.

T1D Program Highlights: The company presented 6-month follow-up data at ADA 2025, showing no safety issues, immune evasion, retained graft survival, and increased C-peptide levels. It reiterated T1D as its lead focus, with plans for a potential IND filing for SC451 in Q2026 and updates later in 2025. The IPSC-derived therapy aims to address the unmet need for T1D treatment, benefiting a global 10M patient population.

Non-T1D Pipeline: Includes programs like SC291 (allo CD19 CART for SLE and cancers), SC262 (allo CD22 CART), and an in vivo CAR T program with SG299, all advancing in 2025-2026 with potential catalysts. Cash runway extends to Q4 2026.

Financials and Valuation: Equity Research from Jefferies reiterates BUY with a price target of $7.00 (up 202%). Market cap is $548.2M. Key risks include funding needs and regulatory challenges.

Opportunity: T1D remains a significant unmet need, with the company highlighting its focus on raising capital to advance programs.